A Study to Investigate the Efficacy and Safety of RG7774 in Patients With Diabetes Mellitus Type 1 or Type 2 With Treatment-Naive Diabetic Retinopathy

PHASE2CompletedINTERVENTIONAL
Enrollment

139

Participants

Timeline

Start Date

June 5, 2020

Primary Completion Date

July 19, 2023

Study Completion Date

July 19, 2023

Conditions
Diabetic Retinopathy
Interventions
DRUG

Placebo

Participants will receive oral placebo matched to RG7774

DRUG

RG7774

Participants will receive oral RG7774

Trial Locations (68)

2000

Sydney Eye Hospital, Sydney

Sydney Retina Clinic and Day Surgery, Sydney

3002

Centre For Eye Research Australia, East Melbourne

3178

Retina Specialists Victoria, Rowville

8021

Clinica Barraquer, Barcelona

8907

Hospital Universitari de Bellvitge; Servicio de Oftalmologia, L'Hospitalet de Llobregat

11572

Ophthalmic Consultants of Long Island, Oceanside

13057

Velocity Clinical Research, East Syracuse

16507

Erie Retinal Surgery, Erie

21740

Cumberland Valley Retina PC, Hagerstown

28210

Charlotte Eye Ear Nose and Throat Associates, Charlotte

28222

Hospital Universitario Puerta de Hierro, Majadahonda

29456

Charleston Neuroscience Institute, Ladson

30060

Marietta Eye Clinic, Marietta

30909

Southeast Retina Center, Augusta

32503

Retina Specialty Institute, Pensacola

32901

Florida Eye Associates, Melbourne

33064

Rand Eye, Deerfield Beach

33143

Medeye Associates, Miami

33711

Retina Vitreous Assoc of FL, St. Petersburg

33805

Florida Retina Consultants, Lakeland

37421

Southeastern Retina Associates Chattanooga, Chattanooga

38138

Charles Retina Institute, Germantown

38671

Deep Blue Retina PLLC, Southaven

47012

Pio del Rio Hortega University Hospital, Valladolid

48105

University of Michigan, Kellogg Eye Center, Ann Arbor

50009

Miguel Servet University Hospital, Zaragoza

60126

Retina Associated Ltd, Elmhurst

60452

University Retina and Macula Associates, PC, Oak Forest

76087

Strategic Clinical Research Group, LLC, Willow Park

77384

Retinal Consultants of Houston, The Woodlands

78215

San Antonio Eye Center, San Antonio

78750

Austin Clinical Research LLC, Austin

79606

Retina Res Institute of Texas, Abilene

80909

Retina Consultants of Southern Colorado PC, Colorado Springs

85016

Arizona Retina and Vitreous Consultants, Phoenix

85710

Retina Associates Tucson, Tucson

87109

Eye Associates of New Mexico, Albuquerque

89502

Sierra Eye Associates, Reno

90502

Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center, Torrance

91006

Win Retina, Arcadia

91204

Global Research Management, Glendale

97225

EyeHealth Northwest, Portland

06385

Retina Group of New England, Waterford

07003

Envision Ocular, LLC, Bloomfield

77384-4167

Retina Consultants of Texas, The Woodlands

91-321

Centrum Medyczne Julianow; Zeglarska, ?ód?

40-594

Gabinet Okulistyczny Prof Edward Wylegala, Katowice

31-070

Centrum Medyczne UNO-MED, Krakow

10-424

Centrum Diagnostyki i Mikrochirurgii Oka LENS, Olsztyn

44-203

LensClinic, Rybnik

00612

Emanuelli Research and Development Center LLC, Arecibo

974 01

Fakultna nemocnica s poliklinikou F.D. Roosevelta, Banská Bystrica

826 06

Klinika Oftalmológie LFUK a UNB, Bratislava

851 07

O?ná klinika UNB a SZU, Bratislava

040 11

3F s.r.o, Košice

911 71

Fakultna nemocnica Trencin, Trenčín

012 07

Fakultna nemocnica s poliklinikou Zilina; Ocne oddelenie, Žilina

08195

Hospital General de Catalunya, San Cugat Del Valles

08025

Hospital Dos de Maig, Barcelona

08036

Hospital Clinic I Provincial, Barcelona

BT12 6BA

Royal Victoria Hospital; Outpatients Department, Belfast

CO4 5JL

Colchester General Hospital, Colchester, Essex

GU2 7XX

Royal Surrey County Hospital; Eye Clinic Research office, Guildford

HU3 2JZ

Hull University Teaching Hospitals NHS Trust, Hull

L7 8XP

Royal Liverpool University Hospital, Liverpool

NG7 2UH

Nottingham University Hospitals NHS Trust, Nottingham

SR2 9HP

Sunderland Eye Infirmary, Sunderland

All Listed Sponsors
lead

Hoffmann-La Roche

INDUSTRY

NCT04265261 - A Study to Investigate the Efficacy and Safety of RG7774 in Patients With Diabetes Mellitus Type 1 or Type 2 With Treatment-Naive Diabetic Retinopathy | Biotech Hunter | Biotech Hunter